Does the media prefer ROIV or IONS?

In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 10 mentions for Roivant Sciences. Ionis Pharmaceuticals' average media sentiment score of 0.48 beat Roivant Sciences' score of 0.09 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IONS or INSM?

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 12 mentions for Insmed. Insmed's average media sentiment score of 0.99 beat Ionis Pharmaceuticals' score of 0.48 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IONS or INCY?

In the previous week, Incyte had 13 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 27 mentions for Incyte and 14 mentions for Ionis Pharmaceuticals. Incyte's average media sentiment score of 0.54 beat Ionis Pharmaceuticals' score of 0.48 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Incyte 8 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor IONS or BNTX?

In the previous week, BioNTech had 14 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 28 mentions for BioNTech and 14 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.48 beat BioNTech's score of 0.07 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to GMAB or IONS?

In the previous week, Ionis Pharmaceuticals had 7 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 7 mentions for Genmab A/S. Ionis Pharmaceuticals' average media sentiment score of 0.48 beat Genmab A/S's score of 0.25 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ionis Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ionis Pharmaceuticals (IONS) Competitors

$45.57 +1.07 (+2.40%)

Closing price 09/28/2026 04:00 PM Eastern

Extended Trading

$45.86 +0.29 (+0.63%)

As of 09:04 AM Eastern

Compare

IONS vs. ROIV, INSM, INCY, BNTX, and GMAB

Should you buy Ionis Pharmaceuticals stock or one of its competitors? Ionis Pharmaceuticals's main competitors and comparable companies include Roivant Sciences (ROIV), Insmed (INSM), Incyte (INCY), BioNTech (BNTX), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings, media sentiment and valuation.

Roivant Sciences has higher earnings, but lower revenue than Ionis Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,233.82	-$299.77M	-$0.53	N/A
Ionis Pharmaceuticals	$944M	8.02	-$381.39M	-$3.46	N/A

In the previous week, Ionis Pharmaceuticals had 4 more articles in the media than Roivant Sciences. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 10 mentions for Roivant Sciences. Ionis Pharmaceuticals' average media sentiment score of 0.48 beat Roivant Sciences' score of 0.09 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals has a net margin of -64.76% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Roivant Sciences presently has a consensus price target of $45.64, suggesting a potential upside of 23.41%. Ionis Pharmaceuticals has a consensus price target of $89.20, suggesting a potential upside of 95.74%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Roivant Sciences has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Summary

Ionis Pharmaceuticals beats Roivant Sciences on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Insmed?

Ionis Pharmaceuticals (NASDAQ:IONS) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ionis Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	8.02	-$381.39M	-$3.46	N/A
Insmed	$606.42M	42.37	-$1.28B	-$4.11	N/A

In the previous week, Ionis Pharmaceuticals had 2 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 12 mentions for Insmed. Insmed's average media sentiment score of 0.99 beat Ionis Pharmaceuticals' score of 0.48 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals has a net margin of -64.76% compared to Insmed's net margin of -76.94%. Ionis Pharmaceuticals' return on equity of -111.08% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Insmed	-76.94%	-123.94%	-44.30%

Ionis Pharmaceuticals currently has a consensus target price of $89.20, indicating a potential upside of 95.74%. Insmed has a consensus target price of $201.87, indicating a potential upside of 71.56%. Given Ionis Pharmaceuticals' higher possible upside, equities analysts clearly believe Ionis Pharmaceuticals is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Ionis Pharmaceuticals has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Summary

Ionis Pharmaceuticals beats Insmed on 10 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Incyte?

Ionis Pharmaceuticals (NASDAQ:IONS) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, earnings, analyst recommendations, institutional ownership, risk and valuation.

In the previous week, Incyte had 13 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 27 mentions for Incyte and 14 mentions for Ionis Pharmaceuticals. Incyte's average media sentiment score of 0.54 beat Ionis Pharmaceuticals' score of 0.48 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Incyte	8 Very Positive mention(s)	6 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus target price of $89.20, indicating a potential upside of 95.74%. Incyte has a consensus target price of $124.80, indicating a potential downside of 0.02%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Ionis Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56

Incyte has a net margin of 27.71% compared to Ionis Pharmaceuticals' net margin of -64.76%. Incyte's return on equity of 29.93% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
Incyte	27.71%	29.93%	22.88%

Incyte has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	8.02	-$381.39M	-$3.46	N/A
Incyte	$5.14B	4.92	$1.29B	$7.85	15.90

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Incyte beats Ionis Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to BioNTech?

Ionis Pharmaceuticals (NASDAQ:IONS) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ionis Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	8.02	-$381.39M	-$3.46	N/A
BioNTech	$3.25B	7.72	-$1.29B	-$7.83	N/A

In the previous week, BioNTech had 14 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 28 mentions for BioNTech and 14 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 0.48 beat BioNTech's score of 0.07 indicating that Ionis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Ionis Pharmaceuticals has a beta of 0.42, suggesting that its stock price is 58% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Ionis Pharmaceuticals presently has a consensus price target of $89.20, suggesting a potential upside of 95.74%. BioNTech has a consensus price target of $126.00, suggesting a potential upside of 27.17%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

BioNTech has a net margin of -63.54% compared to Ionis Pharmaceuticals' net margin of -64.76%. BioNTech's return on equity of -6.86% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%
BioNTech	-63.54%	-6.86%	-6.00%

Summary

BioNTech beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.93	$963M	$1.27	27.84
Ionis Pharmaceuticals	$944M	8.02	-$381.39M	-$3.46	N/A

In the previous week, Ionis Pharmaceuticals had 7 more articles in the media than Genmab A/S. MarketBeat recorded 14 mentions for Ionis Pharmaceuticals and 7 mentions for Genmab A/S. Ionis Pharmaceuticals' average media sentiment score of 0.48 beat Genmab A/S's score of 0.25 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.42, indicating that its share price is 58% less volatile than the broader market.

Genmab A/S has a net margin of 19.08% compared to Ionis Pharmaceuticals' net margin of -64.76%. Genmab A/S's return on equity of 14.89% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Ionis Pharmaceuticals	-64.76%	-111.08%	-17.41%

Genmab A/S presently has a consensus target price of $39.50, indicating a potential upside of 11.71%. Ionis Pharmaceuticals has a consensus target price of $89.20, indicating a potential upside of 95.74%. Given Ionis Pharmaceuticals' higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Ionis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Genmab A/S beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.40B	$3.94B	$7.33B	$13.18B
Dividend Yield	N/A	3.63%	2.52%	14.03%
P/E Ratio	-13.17	13.88	274.70	25.59
Price / Sales	8.02	1,317.27	615.75	83.42
Price / Cash	N/A	40.88	28.02	35.00
Price / Book	15.09	15.38	10.52	6.44
Net Income	-$381.39M	-$22.71M	$3.50B	$360.47M
7 Day Performance	-0.39%	-4.24%	-2.65%	-1.46%
1 Month Performance	-25.36%	-7.81%	-3.76%	-3.75%
1 Year Performance	-28.96%	27.27%	13.56%	3.91%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	3.3963 of 5 stars	$45.57 +2.4%	$89.20 +95.7%	-28.9%	$7.40B	$944M	N/A	1,402
ROIV Roivant Sciences	2.8027 of 5 stars	$38.99 -2.0%	$45.64 +17.0%	+143.8%	$28.73B	$8.26M	N/A	721
INSM Insmed	3.8255 of 5 stars	$121.00 +0.8%	$204.91 +69.3%	-14.1%	$26.21B	$606.42M	N/A	1,664
INCY Incyte	3.0568 of 5 stars	$124.65 -0.5%	$124.05 -0.5%	+50.9%	$25.40B	$5.14B	15.88	2,844	Trending News Analyst Forecast
BNTX BioNTech	3.4165 of 5 stars	$98.00 +2.0%	$126.00 +28.6%	+1.0%	$24.29B	$3.25B	N/A	7,807	Trending News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 9/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ROIV, INSM, INCY, BNTX, and GMAB

How does Ionis Pharmaceuticals compare to Roivant Sciences?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Summary

How does Ionis Pharmaceuticals compare to BioNTech?

Summary

How does Ionis Pharmaceuticals compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. ROIV, INSM, INCY, BNTX, and GMAB

How does Ionis Pharmaceuticals compare to Roivant Sciences?

Which has higher earnings and valuation, ROIV or IONS?

Does the media prefer ROIV or IONS?

Is ROIV or IONS more profitable?

Do analysts recommend ROIV or IONS?

Do institutionals and insiders have more ownership in ROIV or IONS?

Which has more risk and volatility, ROIV or IONS?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Do institutionals and insiders believe in IONS or INSM?

Which has higher earnings & valuation, IONS or INSM?

Does the media refer more to IONS or INSM?

Is IONS or INSM more profitable?

Do analysts recommend IONS or INSM?

Which has more volatility & risk, IONS or INSM?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Does the media favor IONS or INCY?

Which has more risk & volatility, IONS or INCY?

Do analysts recommend IONS or INCY?

Is IONS or INCY more profitable?

Which has preferable earnings and valuation, IONS or INCY?

Do insiders & institutionals believe in IONS or INCY?

Summary

How does Ionis Pharmaceuticals compare to BioNTech?

Do insiders & institutionals have more ownership in IONS or BNTX?

Which has higher earnings and valuation, IONS or BNTX?

Does the media favor IONS or BNTX?

Which has more volatility and risk, IONS or BNTX?

Do analysts prefer IONS or BNTX?

Is IONS or BNTX more profitable?

Summary

How does Ionis Pharmaceuticals compare to Genmab A/S?

Do insiders and institutionals believe in GMAB or IONS?

Which has stronger valuation & earnings, GMAB or IONS?

Does the media refer more to GMAB or IONS?

Which has more risk and volatility, GMAB or IONS?

Is GMAB or IONS more profitable?

Do analysts recommend GMAB or IONS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools